

# Rosemary Sutton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2485072/publications.pdf>

Version: 2024-02-01

132  
papers

6,407  
citations

101543

36  
h-index

71685

76  
g-index

132  
all docs

132  
docs citations

132  
times ranked

8102  
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. <i>Leukemia</i> , 2007, 21, 604-611.	7.2	626
2	The MLL recombinome of acute leukemias in 2017. <i>Leukemia</i> , 2018, 32, 273-284.	7.2	527
3	The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. <i>Nature Genetics</i> , 2015, 47, 330-337.	21.4	405
4	The MLL recombinome of acute leukemias in 2013. <i>Leukemia</i> , 2013, 27, 2165-2176.	7.2	393
5	New insights to the MLL recombinome of acute leukemias. <i>Leukemia</i> , 2009, 23, 1490-1499.	7.2	363
6	Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. <i>Leukemia</i> , 2008, 22, 771-782.	7.2	339
7	Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. <i>Lancet, The</i> , 2010, 376, 2009-2017.	13.7	282
8	A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2013, 45, 1226-1231.	21.4	270
9	<i>ODC1</i> Is a Critical Determinant of <i>MYCN</i> Oncogenesis and a Therapeutic Target in Neuroblastoma. <i>Cancer Research</i> , 2008, 68, 9735-9745.	0.9	200
10	Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. <i>Leukemia</i> , 2007, 21, 706-713.	7.2	139
11	Identification of an oestrus-associated glycoprotein in oviducal fluid of the sheep. <i>Reproduction</i> , 1984, 72, 415-422.	2.6	118
12	Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , 2016, 128, 911-922.	1.4	103
13	Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone. <i>Blood</i> , 2007, 110, 632-639.	1.4	101
14	Detection of IgE- and IgG-binding proteins after electrophoretic transfer from polyacrylamide gels. <i>Journal of Immunological Methods</i> , 1982, 52, 183-194.	1.4	99
15	The diversity of allergens involved in bakers' asthma. <i>Clinical and Experimental Allergy</i> , 1984, 14, 93-107.	2.9	87
16	Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology. <i>Blood</i> , 2017, 129, 2771-2781.	1.4	84
17	Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study. <i>Leukemia</i> , 2016, 30, 32-38.	7.2	81
18	More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling. <i>Blood Advances</i> , 2019, 3, 3393-3405.	5.2	81

#	ARTICLE	IF	CITATIONS
19	Persistent <scp>MRD</scp> before and after allogeneic <scp>BMT</scp> predicts relapse in children with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2015, 168, 395-404.	2.5	66
20	Late Recurrence of Childhood T-Cell Acute Lymphoblastic Leukemia Frequently Represents a Second Leukemia Rather Than a Relapse: First Evidence for Genetic Predisposition. <i>Journal of Clinical Oncology</i> , 2011, 29, 1643-1649.	1.6	62
21	Down syndrome and leukemia: insights into leukemogenesis and translational targets. <i>Translational Pediatrics</i> , 2015, 4, 76-92.	1.2	60
22	The Increasing Adenine Nucleotide Concentration and the Maturation of Rat Liver Mitochondria during Neonatal Development. <i>Differentiation</i> , 1979, 12, 15-21.	1.9	56
23	Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2009, 146, 292-299.	2.5	56
24	High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. <i>Leukemia</i> , 2013, 27, 1497-1503.	7.2	54
25	High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. <i>Haematologica</i> , 2017, 102, e490-e493.	3.5	52
26	The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemia. <i>Blood Advances</i> , 2020, 4, 930-942.	5.2	52
27	Immunoglobulin E antibodies to ingested cereal flour components: studies with sera from subjects with asthma and eczema. <i>Clinical and Experimental Allergy</i> , 1982, 12, 63-74.	2.9	51
28	AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2015, 126, 1193-1202.	1.4	50
29	Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients. <i>Haematologica</i> , 2017, 102, 541-551.	3.5	49
30	Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL. <i>Blood Advances</i> , 2019, 3, 148-157.	5.2	48
31	Antigens and allergens from the common house dust mite <i>Dermatophagoides pteronyssinus</i> . <i>Journal of Allergy and Clinical Immunology</i> , 1984, 74, 132-141.	2.9	47
32	The differentiation of animal mitochondria during development. <i>Trends in Biochemical Sciences</i> , 1980, 5, 23-27.	7.5	43
33	Effective Targeting of the P53â€“MDM2 Axis in Preclinical Models of Infant <i>MLL</i>-Rearranged Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2015, 21, 1395-1405.	7.0	43
34	Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLLâ€“USP2 fusions. <i>Leukemia</i> , 2019, 33, 2306-2340.	7.2	41
35	Carbohydrate Metabolism of Cactus in a Desert Environment. <i>Plant Physiology</i> , 1981, 68, 784-787.	4.8	40
36	Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study. <i>Leukemia</i> , 2021, 35, 2978-2982.	7.2	40

#	ARTICLE	IF	CITATIONS
37	Polyloid cells in blastocysts and early fetuses from Australian Merino sheep. <i>Reproduction</i> , 1986, 78, 439-446.	2.6	38
38	FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation. <i>Leukemia</i> , 2013, 27, 1053-1062.	7.2	38
39	Allergen discs prepared from nitrocellulose: Detection of IgE binding to soluble and insoluble allergens. <i>Journal of Immunological Methods</i> , 1984, 73, 139-145.	1.4	36
40	Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial. <i>Lancet Haematology</i> , 2019, 6, e204-e216.	4.6	36
41	The transport and accumulation of adenine nucleotides during mitochondrial biogenesis. <i>Biochemical Journal</i> , 1980, 192, 75-83.	3.7	34
42	Outcome of Central Nervous System Relapses In Childhood Acute Lymphoblastic Leukaemia – Prospective Open Cohort Analyses of the ALLR3 Trial. <i>PLoS ONE</i> , 2014, 9, e108107.	2.5	34
43	Hormone-initiated maturation of rat liver mitochondria after birth. <i>Biochemical Journal</i> , 1980, 186, 361-367.	3.7	33
44	Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols. <i>Haematologica</i> , 2020, 105, 1887-1894.	3.5	33
45	Oestrogen and seasonal effects on the production of an oestrus-associated glycoprotein in oviducal fluid of sheep. <i>Reproduction</i> , 1986, 77, 645-653.	2.6	32
46	Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study. <i>Lancet Haematology</i> , 2021, 8, e55-e66.	4.6	32
47	Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2009, 88, 897-905.	1.8	31
48	Highly sensitive MRD tests for ALL based on the IKZF1 3q6 microdeletion. <i>Leukemia</i> , 2012, 26, 1414-1416.	7.2	30
49	Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia. <i>International Journal of Cancer</i> , 2020, 146, 1902-1916.	5.1	30
50	A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2014, 4, e232-e232.	6.2	28
51	Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression. <i>British Journal of Cancer</i> , 2018, 118, 1000-1004.	6.4	28
52	A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children. <i>British Journal of Haematology</i> , 2018, 180, 550-562.	2.5	28
53	Targeted Next-Generation Sequencing for Detecting MLL Gene Fusions in Leukemia. <i>Molecular Cancer Research</i> , 2018, 16, 279-285.	3.4	27
54	Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. <i>European Journal of Cancer</i> , 2021, 151, 175-189.	2.8	27

#	ARTICLE	IF	CITATIONS
55	Mechanism of relapse in pediatric acute lymphoblastic leukemia. <i>Cell Cycle</i> , 2008, 7, 1315-1320.	2.6	25
56	Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia?. <i>Blood Advances</i> , 2017, 1, 1473-1477.	5.2	25
57	A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts. <i>Oncotarget</i> , 2016, 7, 60475-60490.	1.8	24
58	Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions. <i>Cancer Letters</i> , 2017, 408, 92-101.	7.2	23
59	Germline deletion of ETV6 in familial acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 1039-1046.	5.2	21
60	Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant. <i>Cancer Research</i> , 2016, 76, 4579-4591.	0.9	20
61	Sensitive and Specific Measurement of Minimal Residual Disease in Acute Lymphoblastic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 201-210.	2.8	18
62	Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016, 7, 58728-58742.	1.8	18
63	Improving the Identification of High Risk Precursor B Acute Lymphoblastic Leukemia Patients with Earlier Quantification of Minimal Residual Disease. <i>PLoS ONE</i> , 2013, 8, e76455.	2.5	17
64	Bone Marrow Recovery by Morphometry during Induction Chemotherapy for Acute Lymphoblastic Leukemia in Children. <i>PLoS ONE</i> , 2015, 10, e0126233.	2.5	17
65	Cerebral Vasculitis in X-linked Lymphoproliferative Disease Cured by Matched Unrelated Cord Blood Transplant. <i>Journal of Clinical Immunology</i> , 2015, 35, 604-609.	3.8	17
66	Endometrial expression of mRNA encoding insulin-like growth factors I and II and IGF-binding proteins 1 and 2 in early pregnant ewes. <i>Reproduction</i> , 1997, 111, 7-13.	2.6	16
67	Quantitative Phosphotyrosine Profiling of Patient-Derived Xenografts Identifies Therapeutic Targets in Pediatric Leukemia. <i>Cancer Research</i> , 2016, 76, 2766-2777.	0.9	16
68	Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia. <i>Thrombosis Research</i> , 2019, 178, 132-138.	1.7	16
69	Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia. <i>Haematologica</i> , 2022, 107, 635-643.	3.5	16
70	Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28922.	1.5	16
71	Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin. <i>British Journal of Cancer</i> , 2021, 125, 55-64.	6.4	16
72	Two cases of hypereosinophilia and high-risk acute lymphoblastic leukemia. <i>Leukemia</i> , 2008, 22, 1463-1465.	7.2	15

#	ARTICLE	IF	CITATIONS
73	Evidence for the Repair of Ozone-Induced Membrane Injury. <i>American Journal of Botany</i> , 1977, 64, 404.	1.7	15
74	Characterisation of a glycoprotein in oviductal fluid by two-dimensional electrophoresis and lectin binding to protein gel blots. <i>Electrophoresis</i> , 1985, 6, 516-520.	2.4	13
75	<i>MYC</i> Protooncogenes of Wool and Hair Growth <sup>a</sup> . <i>Annals of the New York Academy of Sciences</i> , 1991, 642, 326-338.	3.8	13
76	The adenine nucleotide translocator in foetal, suckling and adult rat liver mitochondria. <i>Biochemical and Biophysical Research Communications</i> , 1978, 80, 193-198.	2.1	12
77	Improving minimal residual disease detection in precursor B-ALL based on immunoglobulin-Îº and heavy-chain gene rearrangements. <i>Leukemia</i> , 2008, 22, 2265-2267.	7.2	12
78	Determining the Repertoire of IGH Gene Rearrangements to Develop Molecular Markers for Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 194-200.	2.8	11
79	Evidence for repair of ozone induced membrane injury: Alteration in sugar uptake. <i>Atmospheric Environment</i> , 1977, 11, 273-275.	1.0	10
80	A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH. <i>Cancer Genetics</i> , 2017, 216-217, 86-90.	0.4	10
81	Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study. <i>Lancet Haematology</i> , 2021, 8, e700-e710.	4.6	10
82	Ovarian response to PMSG and GnRH in ewes immunised against oestradiol-17 beta. <i>Veterinary Record</i> , 1987, 120, 590-592.	0.3	10
83	The Import of Carbamoyl-Phosphate Synthase into Mitochondria from Foetal Rat Liver. <i>FEBS Journal</i> , 1982, 125, 401-406.	0.2	9
84	Genetic characterization and therapeutic targeting of <i>MYC</i> -rearranged T cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2019, 185, 169-174.	2.5	9
85	<i>COBL</i> is a novel hotspot for <i>IKZF1</i> deletions in childhood acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016, 7, 53064-53073.	1.8	9
86	Clonal dynamics in pediatric B-cell precursor acute lymphoblastic leukemia with very early relapse. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29361.	1.5	9
87	Towards gene transfer into ruminant embryos: Effect of centrifugation. <i>Theriogenology</i> , 1984, 21, 248.	2.1	8
88	Growth factor expression in skin during wool follicle development. <i>Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology</i> , 1995, 110, 697-705.	1.6	8
89	Ovarian Response to PMSC Treatment in Ewes Immunized against Oestradiol-17Å. <i>Australian Journal of Biological Sciences</i> , 1985, 38, 339.	0.5	8
90	Tyr-TGFÎ± transgenic mice develop ocular melanocytic lesions. <i>Melanoma Research</i> , 2002, 12, 435-439.	1.2	7

#	ARTICLE	IF	CITATIONS
91	Bone marrow fibrosis and vascular density lack prognostic significance in childhood acute lymphoblastic leukaemia. <i>Leukemia</i> , 2010, 24, 1537-1538.	7.2	7
92	IKZF1 Deletions with COBL Breakpoints Are Not Driven by RAG-Mediated Recombination Events in Acute Lymphoblastic Leukemia. <i>Translational Oncology</i> , 2019, 12, 726-732.	3.7	7
93	Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma. <i>British Journal of Cancer</i> , 2022, 126, 482-491.	6.4	7
94	Enrichment of atypical hyperdiploidy and IKZF1 deletions detected by SNP-microarray in high-risk Australian AIEOP-BFM B-cell acute lymphoblastic leukaemia cohort. <i>Cancer Genetics</i> , 2020, 242, 8-14.	0.4	6
95	Whole Genome Sequence Analysis of 22 MLL Rearranged Infant Acute Lymphoblastic Leukemias Reveals Remarkably Few Somatic Mutations: A Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project. <i>Blood</i> , 2011, 118, 69-69.	1.4	6
96	Post Induction Minimal Residual Disease Levels Identifies a Group of High Risk Relapsed Childhood Acute Lymphoblastic Leukemia (rALL) with a Favorable Outcome Independent of Induction Therapy. <i>Blood</i> , 2015, 126, 1294-1294.	1.4	6
97	An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL. <i>Blood Advances</i> , 2021, 5, 5574-5583.	5.2	6
98	Differential diagnosis of paediatric bone pain: Acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2012, 36, 521-523.	0.8	5
99	Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL. <i>Bone Marrow Transplantation</i> , 2016, 51, 1279-1282.	2.4	5
100	Genome-Wide Association Meta-Analysis of Single-Nucleotide Polymorphisms and Symptomatic Venous Thromboembolism during Therapy for Acute Lymphoblastic Leukemia and Lymphoma in Caucasian Children. <i>Cancers</i> , 2020, 12, 1285.	3.7	5
101	Abstract 4869: Whole genome sequence analysis of MLL rearranged infant acute lymphoblastic leukemias reveals remarkably few somatic mutations: A Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project. , 2012, , .		4
102	Correlation between a 10â€color flow cytometric measurable residual disease (<sc>MRD</sc>) analysis and molecular <sc>MRD</sc> in adult <sc>Bâ€acute</sc> lymphoblastic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2022, 102, 115-122.	1.5	4
103	Two novel cases of <i>NUTM1</i>â€rearranged Bâ€cell acute lymphoblastic leukaemia presenting with highâ€risk features. <i>British Journal of Haematology</i> , 2022, 196, 1407-1411.	2.5	4
104	Embryonic chromosomal abnormalities and reproductive wastage in Fecundin treated and control Merino ewes. <i>Theriogenology</i> , 1985, 23, 211.	2.1	3
105	Isolated testicular relapse after allo-SCT in boys with ALL: outcome without second transplant. <i>Bone Marrow Transplantation</i> , 2010, 45, 397-399.	2.4	3
106	Highâ€risk Bâ€cell acute lymphoblastic leukaemia presenting with hypereosinophilia and acquiring a novel <i>PAX5</i> fusion on relapse. <i>British Journal of Haematology</i> , 2020, 191, 301-304.	2.5	3
107	Prognostic Value of Rare IKZF1 deletions in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia: An International Collaborative Study. <i>Blood</i> , 2014, 124, 368-368.	1.4	3
108	Towards gene transfer into ruminant embryos: Factors affecting the supply of embryos. <i>Theriogenology</i> , 1984, 21, 222.	2.1	2



#	ARTICLE	IF	CITATIONS
109	Optimization of a clofarabine-based drug combination regimen for the preclinical evaluation of pediatric acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28133.	1.5	2
110	Addition of Thiotepa to Total Body Irradiation and Cyclophosphamide Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2068-2074.	2.0	2
111	CKLF and IL1B transcript levels at diagnosis are predictive of relapse in children with pre-B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 171-175.	2.5	2
112	High-Annealing-Temperature PCR (HAT-PCR) Enables Sensitive Quantification of Minimal Residual Disease (MRD) in Blood in Acute Lymphoblastic Leukaemia (ALL). <i>Blood</i> , 2018, 132, 2831-2831.	1.4	2
113	MLL-USP2: An Underestimated New Entity of MLL-Rearranged Leukemia Identified By NGS Analysis. <i>Blood</i> , 2018, 132, 3920-3920.	1.4	2
114	Clinical Predictors of Venous Thromboembolism during Therapy for Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 1182-1182.	1.4	2
115	Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions. <i>British Journal of Cancer</i> , 2022, 127, 908-915.	6.4	2
116	Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia. <i>British Journal of Cancer</i> , 2020, 123, 742-751.	6.4	1
117	High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk Adapted Treatment. <i>Blood</i> , 2015, 126, 1419-1419.	1.4	1
118	Comparison of MRD Levels and Gene Expression Patterns in MLL-R Versus Non-MLL Infant ALL. <i>Blood</i> , 2016, 128, 1740-1740.	1.4	1
119	The Clinical Relevance Of Genetics In Predicting Outcome After a First Relapse In Children With B-Cell Precursor Acute Lymphoblastic Leukaemia. <i>Blood</i> , 2013, 122, 2566-2566.	1.4	1
120	Sensitive Measurement of Minimal Residual Disease in Blood by High Annealing Temperature-PCR. <i>Journal of Molecular Diagnostics</i> , 2022, , .	2.8	1
121	PCR for monoclonal gene rearrangements can differentiate infantile acute lymphoblastic leukemia from cytomegalovirus infection. <i>Leukemia Research</i> , 2005, 29, 111-112.	0.8	0
122	252A ORAL Relapse in children with acute lymphoblastic leukaemia is associated with selection of a pre-existing drug resistance subclone. <i>European Journal of Cancer, Supplement</i> , 2006, 4, 81.	2.2	0
123	Induction of stem cell features in all cells by microenvironmental factors. <i>Experimental Hematology</i> , 2015, 43, S53.	0.4	0
124	Age matters in ALL. <i>British Journal of Haematology</i> , 2018, 181, 429-430.	2.5	0
125	Use of Thiotepa in Hematopoietic Stem Cell Transplantation for Paediatric Acute Lymphoblastic Leukaemia: An Australian and New Zealand Children's Haematology/Oncology Group Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S310.	2.0	0
126	Analytical Quality Controls for ddPCR Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia. <i>Clinical Chemistry</i> , 2021, 67, 1373-1383.	3.2	0



#	ARTICLE	IF	CITATIONS
127	Mitoxantrone Improves the Outcome of Children with Central Nervous System (CNS) Involvement at First Relapse of Acute Lymphoblastic Leukemia (ALL)-Results of the International ALLR3 Study. <i>Blood</i> , 2010, 116, 3303-3303.	1.4	0
128	MRD Monitoring Using Minor-BCR-ABL1 Genomic Breakpoint in Childhood ALL Identifies a Subgroup with Distinct Biology and a Very Poor Prognosis. <i>Blood</i> , 2015, 126, 3727-3727.	1.4	0
129	Evaluation of Patient-Derived Xenografts for Modeling Outcome of Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 3759-3759.	1.4	0
130	Abstract B21: Genetic characterization and therapeutic targeting of MYC translocated pediatric T-cell acute lymphoblastic leukemia. <i>Cancer Research</i> , 2016, 76, B21-B21.	0.9	0
131	Identification of Multiple, Patient-Specific MLL Fusion Transcript Isoforms in Childhood Leukemia Using Anchored Multiplex PCR-Based Enrichment (AMP-E). <i>Blood</i> , 2016, 128, 2908-2908.	1.4	0
132	Quantitative Analysis of MLL Fusion Transcripts By Droplet Digital PCR to Monitor Minimal Residual Disease in MLL-Rearranged Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2746-2746.	1.4	0